1.Previous
3.Next

of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral fractures by 62%. Risedronate has also been shown to reduce the risk of hip fractures.

After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped. In those at higher risk, ten years of medication by mouth or six years of intravenous treatment may be used.

Cancer

Bisphosphonates reduce the risk of fracture and bone

1.Previous
3.Next